Last reviewed · How we verify
Topiramate coated tablet
At a glance
| Generic name | Topiramate coated tablet |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Head-to-head Study of Erenumab Against Topiramate in Patients With Episodic and Chronic Migraine (PHASE4)
- Treatment of Obesity With Topiramate in Patients With Polycystic Ovary Syndrome (PHASE4)
- Topiramate Bioequivalence Study Brazil - Fast (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Topiramate coated tablet CI brief — competitive landscape report
- Topiramate coated tablet updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI